An ANOCEF Genomic and Transcriptomic Microarray Study of the Response to Irinotecan and Bevacizumab in Recurrent Glioblastomas
Figure 3
Progression-free survival according to Gravendeel et al. [8] and Verhaak et al. [7] molecular subtypes. GBMs assigned to IGS-18 (dashed line) had a shorter PFS after bevacizumab/irinotecan than those assigned to IGS-22 and IGS-23 (plain line) (3.2 months versus 9.4 months, ). GBMs classified as classical (dashed line) had a shorter PFS than those classified as nonclassical (2.2 months versus 8.3 months, ).
